Keyword: Johnson & Johnson

For years, J&J and Pfizer-Astellas have been the players in their class of prostate-cancer drugs. But strong new safety data could make Bayer a threat.

If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.

Facing “historic” liabilities from lawsuits claiming its products caused cancer, J&J supplier Imerys Talc America filed for bankruptcy Wednesday.

FluGen said its intranasal, "universal" flu vaccine helped protect trial participants against a "highly mismatched" strain.

When it comes to Xtandi in hormone-sensitive prostate cancer, Pfizer and Astellas are “really excited." And new data shows they have reason to be.

Top PBM Express Scripts said that its efforts saved clients $45 billion in 2018, and its clients' drug costs grew just 0.4% last year.

Johnson & Johnson is the first pharma to announce it will put drug list prices directly in TV ads, self-regulating ahead of a proposed regulation.

Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.

J&J is counting on Erleada to carry the prostate cancer baton as Zytiga battles generics. And it just got one step closer to a new indication.

Xtandi is crushing J&J’s Erleada in the nonmetastatic, castration-resistant prostate cancer market—according to Pfizer executives, at least.